Aptahem has started the production of GMP certified Apta-1 for clinical trials
Aptahem can today announce that the production of Good Manufacturing Practice (GMP) manufacturing of the drug candidate Apta-1 has started at the collaboration partner LGC Biotechnologies’ facilities in the USA, with planned delivery date in early 2022. The GMP manufactured Apta-1 will be used in a product which can be administered to humans in a clinical trial.Further process development for the GMP manufacturing has been successful with both improved quality and exchange. Aptahem’s partner LGC has yet again improved the CoGs (Cost of Goods) which is an important part in creating an